New RNA-based Therapy Combats Melanoma in Mouse Models

Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.

Related Keywords

Ohio ,United States ,Ohio State University ,East Harlem ,New York ,American ,Brian Brown ,Yizhou Dong ,Binbin Deng Ohio State University ,Yonger Xue Ohio State University ,National Institute ,Icahn School Of Medicine At Mount Sinai ,Astrazeneca ,Shi Du Ohio State University ,Icahn Genomics Institute ,Merck Co ,Davidw Mccomb Ohio State University ,Professor Of Oncological Sciences ,Jingyue Yan Ohio State University ,Health System ,Novo Nordisk ,Yuebao Zhang Ohio State University ,Chang Wang Ohio State University ,Yichen Zhong Ohio State University ,Association Of American Medical Colleges ,Mount Sinai Health System ,Dianad Kang Ohio State University ,Xucheng Hou Ohio State University ,National Institutes Of Health ,National Cancer Institute ,Icahn School ,Mount Sinai ,Nature Nanotechnology ,Oncological Sciences ,Icahn Mount ,Associate Director ,Cancer Immunity Cycle ,Yuebao Zhang ,Xucheng Hou ,Icahn Mount Sinai ,Yonger Xue ,Jingyue Yan ,Yichen Zhong ,Chang Wang ,Binbin Deng ,General Medical Sciences ,National Institutes ,American Medical Colleges ,Mount Sinai Innovation Partners ,New York City ,Upper East Side ,Melanoma ,Rna ,